Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Catheter Precision (VTAK) over the last 5 years, with Q3 2025 value amounting to $11263.0.

  • Catheter Precision's Gains from Sales and Divestitures changed N/A to $11263.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11263.0, marking a year-over-year change of. This contributed to the annual value of $1660.0 for FY2022, which is N/A changed from last year.
  • Catheter Precision's Gains from Sales and Divestitures amounted to $11263.0 in Q3 2025.
  • In the past 5 years, Catheter Precision's Gains from Sales and Divestitures registered a high of $100000.0 during Q2 2025, and its lowest value of $26.0 during Q1 2023.
  • In the last 4 years, Catheter Precision's Gains from Sales and Divestitures had a median value of $17992.0 in 2021 and averaged $26358.3.
  • The largest annual percentage gain for Catheter Precision's Gains from Sales and Divestitures in the last 5 years was 195371.25% (2023), contrasted with its biggest fall of 9995.89% (2023).
  • Catheter Precision's Gains from Sales and Divestitures (Quarter) stood at $31388.0 in 2021, then tumbled by 94.71% to $1660.0 in 2022, then skyrocketed by 1466.27% to $26000.0 in 2023, then plummeted by 56.68% to $11263.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $11263.0 for Q3 2025, versus $100000.0 for Q2 2025 and $49999.0 for Q1 2025.